JAMA | Risk-Based vs Annual Breast Cancer Screening

This landmark JAMA 2025 trial showed that PRS-powered risk-based breast cancer screening was non-inferior to annual screening and was associated with an approximately one-third lower rate of advanced cancer.
This landmark JAMA 2025 WISDOM trial showed that PRS-powered risk-based breast cancer screening was non-inferior to annual screening and was associated with an approximately one-third lower rate of advanced (stage ≥IIB) cancers (30.0 vs 48.0 per 100,000 person-years), with nearly doubled uptake of preventive therapy among the highest-risk women, establishing PRS-guided screening as a scalable and clinically sound strategy.